Assembly


The Assembly of Psychedelic Research Centers will gather representatives from university-affiliated Psychedelic Centers to participate in Psychedemia’s closing panel on August 14th. This closing panel is titled “Charting the Future of Psychedelic Studies: An Assembly of Psychedelic Research Centers.” Listed here are the confirmed participating centers.

The Psychedelic Studies Research Program (PSRP) at the University of Toronto Mississauga is dedicated to understanding the effects of microdosing. The researchers at PSRP are a team of experts with varied backgrounds in neuroscience, clinical psychology, creative thinking, psychotherapy, and more.

The Center for Psychedelic Research and Therapy at Dell Medical School at The University of Texas at Austin aims to advance the application of psychedelics for the treatment of mental health disorders through impactful clinical research. Additionally, the center — the first of its kind in Texas — looks to improve the health of those suffering from severe depression, anxiety and PTSD through psychedelic-assisted psychotherapy and research focused heavily on military veterans and adults affected by early childhood trauma.

The mission of the UW–Madison Transdisciplinary Center for Research in Psychoactive Substances is to support research and educational activities regarding psychedelic drugs and related compounds. The center supports the UW–Madison campus and the Wisconsin community with research infrastructure, such as drug dosing rooms, treatment facilitator training, and education. Although some work focuses on drugs with a clear psychedelic effect, related substances may have clinical effects on mood or behavior without the psychedelic experience, thus the use of the term “psychoactive.”

The Translational Psychedelic Research (TrPR) Program at the University of California San Francisco brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA, and related compounds impact the brain and other organ systems. We combine innovative basic and clinical research approaches to answer key questions about the mechanisms, safety, and efficacy of psychedelics for specific health conditions. Our goal is to accelerate progress towards impactful and accessible psychedelic treatments.

The mission of the Center for Psychedelic Drug Research and Education (CPDRE) is to explore and advance the research about psychedelic drugs and their effects, and to disseminate the knowledge about psychedelics through education initiatives at the college, university, and local, national, and international locations.

Combining scientific research, training, and public education, the UC Berkeley Center for the Science of Psychedelics (BCSP) is a new interdisciplinary initiative to explore the psychological and biological effects of psychedelic compounds as well as their spiritual and cultural roles. The BCSP: 1) Investigates short- and long-term effects of psychedelics on human cognition, perception, and emotion; 2) Assists in the training of practitioners to support the use of these medicines in culturally appropriate, spiritually significant, and medically safe ways; and 3) Offers authoritative, evidence-based, and culturally inclusive journalism about the field through a public education initiative housed at the UC Berkeley Graduate School of Journalism.

For over 15 years the Johns Hopkins Psychedelic Research Unit has been the preeminent and most productive research team in the United States conducting human research with psychedelics. They have shown breathtaking scientific productivity, having published more than 50 peer-reviewed manuscripts on psychedelics, including 15 published laboratory studies.

Founded in 2022, the Center for Integrated Psychedelic Science (CIPS) at Duke University is a multidisciplinary collaboration of scholars, scientists, and clinicians working to advance psychedelic science across the translational research spectrum. Our team specifically investigates the mechanistic, phenomenological, therapeutic, and relational effects of psychedelic compounds, as well as their creative, self-enhancing, and sociocultural roles. Drugs of focus include: classic hallucinogens (psilocybin, LSD, mescaline, DMT, ayahuasca), dissociatives (ketamine), and entactogens (MDMA).

The NYU Langone Health Center for Psychedelic Medicine has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Interactive platforms of research and education span the three core areas, providing the necessary infrastructure to generate knowledge, train scientists and clinicians, and ensure accurate dissemination of information surrounding the clinical use of psychedelics.

Located at Mount Sinai and the James J. Peters Department of Veterans Affairs Medical Center, the Center for Psychedelic Psychotherapy and Trauma Research examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Center is initially focusing on MDMA-assisted psychotherapy and psilocybin but will expand to studying psychedelic-assisted therapy with other compounds. Using clinical trials, computational genetics, molecular biology, blood samples, and neuroimaging, they hope to accelerate understanding of how MDMA and psilocybin work. The center will also hold clinical trainings for therapists in anticipation of FDA approval and lead public and scientific education, including a monthly lecture series.